Integrating phosphoproteomics into the clinical management of prostate cancer
详细信息 查看全文
- 作者：Larry C. Cheng ; Victor M. Tan ; Shridar Ganesan…
- 关键词：Biomarkers ; Clinical diagnostics ; Clinical trial design ; Kinase inhibitors ; Pharmacotherapy ; Phosphoproteomics ; Precision medicine ; Prostate cancer ; Mass spectrometry
- 刊名：Clinical and Translational Medicine
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：6
- 期：1
- 全文大小：1556KB
- 刊物主题：Medicine/Public Health, general;
- 出版者：Springer Berlin Heidelberg
- ISSN：2001-1326
- 卷排序：6
文摘
Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic.